ATS Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.0%projected annual EPS growth
FY Revenue (est.)
$2Bnext fiscal year
FY EPS (est.)
$0.77next fiscal year
Monitoring Framework
Key Performance Indicators
Order Bookings Quarterly3B
Order Backlog Quarterly2B
Adjusted EBITDA Margin Quarterly1,390.0%Target: 15.0%
Net Debt to Pro Forma Adjusted EBITDA Leverage Ratio Quarterly2.8xTarget: Below 2.0x
Watch Items
- Transportation-related business restructuring and cost realignmentTrigger: Removal of approximately $50 million in dilutive revenuesAction: Consolidate remaining transportation-focused standalone divisions and address excess facility capacity to expand margins.
- Life Sciences segment capital investment cyclesTrigger: Decline in organic Order Bookings due to customer capital cycle timingAction: Monitor diversification into radiopharmaceutical applications and medical device automation outside of autoinjector (GLP-1) assembly equipment.
Research as of 20 Jun 2026